In comparison, by using the model applied here, only cells of the tumor microenvironment (e.g., myeloid cells, endothelial cells) possess Ccr2-deficiency, while glioma cells still express Ccr2, hence retaining functionality towards CCL2 and other signals. This evidence concerns the gene CCL2 and neoplasm.